Parradee Kietsirikul Introduction Last year, we saw an uptick in M&A from big pharma to combat the significant drug patent cliff later in the decade. Amongst the worst anticipated patents cliffs is Bristol Myers Squibb (NYSE:BMY) who announced a number of deals into the end of 2023. Last year former COO and now current CEO Chris Boerner revised the $$10bn-13bn sales target for new drugs by 2025 to $$10bn by 2026, raising concerns over the company ability to completely offset patent loss in later years. Op ...